We report a phase 1 study to examine the safety and recommended dose of the oral protein kinase C-beta inhibitor (anti-angiogenic) enzastaurin in combination with single-agent temozolomide. The study was conducted in patients with recurrent glioblastoma or newly diagnosed disease that was not treatable with standard (chemo)radiotherapy. Patients were treated with standard dose temozolomide (200 mg/m 2 for 5 days every 4 weeks) together with daily oral enzastaurin. Three dose levels of enzastaurin were investigated: 250 mg daily (OD), 500 mg OD, and 250 mg twice daily (BID). Dose-limiting toxicity was determined in the first 2 cycles, but treatment continued until limiting toxicity or disease progression was identified. Twenty-eight patients were enrolled. No dose-limiting toxicity was noted at 250 mg OD or 500 mg OD. However, at 250 mg BID, 2 dose-limiting episodes of thrombocytopenia were noted. The recommended dose for enzastaurin in combination with standard 4-weekly temozolomide is therefore 500 mg OD. The pharmacokinetics of enzastaurin in combination with temozolomide was evaluated. Temozolomide did not appear to effect enzastaurin exposures at the 250 mg or 500 mg OD dose levels.

, , , ,
doi.org/10.1093/neuonc/nor221, hdl.handle.net/1765/63123
Neuro-Oncology
Department of Neurology

Rampling, R, Sanson, M, Gorlia, T.S, Lacombe, D, Lai, C, Gharib, S.A, … van den Bent, M.J. (2012). A phase i study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054). Neuro-Oncology, 14(3), 344–350. doi:10.1093/neuonc/nor221